Log in to save to my catalogue

Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX...

Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1907317281

Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial

About this item

Full title

Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial

Publisher

England: Elsevier Ltd

Journal title

The lancet oncology, 2017-06, Vol.18 (6), p.770-778

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

Subjects

Subjects and topics

More information

Scope and Contents

Contents

Summary Background Pancreatic cancer statistics are dismal, with a 5-year survival of less than 10%, and more than 50% of patients presenting with metastatic disease. Metabolic reprogramming is an emerging hallmark of pancreatic adenocarcinoma. CPI-613 is a novel anticancer agent that selectively targets the altered form of mitochondrial energy met...

Alternative Titles

Full title

Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_1907317281

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1907317281

Other Identifiers

ISSN

1470-2045

E-ISSN

1474-5488

DOI

10.1016/S1470-2045(17)30314-5

How to access this item